Teva slapped with €463M fine over accusations it stymied Copaxone competition in Europe
Fierce Pharma
OCTOBER 31, 2024
Some two years after the European Commission accused Teva of meddling with the competition for its former multiple sclerosis blockbuster Copaxone, the other shoe has finally dropped. | million euros over allegations that the company “[abused] its dominant market position to delay competition” to Copaxone across multiple EU member states.
Let's personalize your content